Anavex Life Sciences Corp (AVXL)

[F1ash]

... by keeping the therapeutic dose at a steady level in the body for longer periods of time.

That’s the problem.

“But a very simple way to remember it is that the average Css is the total exposure (AUC) over one dosing interval divided by the duration of the dosing interval.”

Higher bioavailability should mean higher AUC and the tolerability issue would probably resurface even at the lower dose imho.

If I remember correctly, the Sullivan article said they were trying to figure out how to achieve higher concentrations without causing the side effects, so lowering the dose by increasing the bioavailability doesn’t seem like it would solve that particular problem imho.